Zhitong Financial App News, Enhua Pharmaceutical (002262.SZ) announced that Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd. (“Enhua Hexin”), a wholly-owned subsidiary of the company, and Teva Pharmaceutical Investments Singapore PTE LTD (“TEVA”) signed Antitan on February 22, 2024Exclusive commercialization license and cooperation agreement for (deuterabenazine tablets) (abbreviation: “antaitane” or “licensed product”) products. The agreement period is from February 22, 2024 to February 22, 2029. Enhua Hexin obtained exclusive commercialization rights for TEVA Antitan in mainland China (“Licensed Area”). As consideration for the rights and licenses granted by TEVA or its affiliates in accordance with the cooperation agreement, NWA and its affiliates shall pay a license fee of 30 million US dollars to TEVA or its affiliates.

According to reports, antitan involved in this transaction is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the US Food and Drug Administration (FDA) in 2017. It was approved by China's National Drug Administration in 2020 to treat chorea and tardive movement disorder (TD) related to Huntington's disease (HD) in adults, and entered the medical insurance catalogue through national health insurance negotiations that year. In the field of central nervous system, through this cooperation, Antitan will further enrich the company's product line in the central nervous system field. In terms of marketing, it will share expert networks and clinical resources with the company's existing key varieties in this field, promote mutual promotion and common development, and form effective collaboration.